Skip to main contentSkip to navigation
Sirius Investors

Damora Therapeutics, Inc. (GLTO) Investment Research Dashboard

About Damora Therapeutics, Inc. (GLTO) stock analysis

Get live GLTO stock price $21.58, comprehensive Damora Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time GLTO stock data and investment insights.

21.58
3.36%Today
Market Cap
34.47M
Volume
609
52W High
38.33
52W Low
2.01

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that target...

Company Information

CEO
Jennifer A. Jarrett
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
7

Contact Information

Address
Building 23
Country
US

Investment Analysis & Business Insights

Healthcare
Medical - Pharmaceuticals

Investment Highlights

Strong presence in the Healthcare sector with established market position

Listed on major US exchange (NASDAQ) providing liquidity and transparency

Higher growth potential with elevated volatility (Beta: 1.60)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Damora Therapeutics, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Damora Therapeutics, Inc.
  • Investors should consider how Damora Therapeutics, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

34.47M

P/E Ratio (TTM)

-1.78

Beta

1.60

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

84/100 ⭐⭐⭐⭐⭐

Overall
+0.2%
NYSE
+0.7%
NASDAQ
-0.2%
Sector1D1W1MP/EScore
Financial Services+0.3%+0.9%+3.0%19.0
85/100⭐⭐⭐⭐⭐
Healthcare+0.2%+1.0%+4.1%23.5
84/100⭐⭐⭐⭐⭐
Real Estate+1.8%+2.1%-0.3%29.7
72/100⭐⭐⭐⭐⭐
Communication Services+0.7%-2.5%+2.8%21.8
62/100⭐⭐⭐⭐
Basic Materials+0.9%+0.4%-1.3%24.9
55/100⭐⭐⭐⭐
Consumer Defensive+0.8%-0.0%-0.9%28.7
53/100⭐⭐⭐
Utilities-0.7%+2.0%-1.3%25.2
52/100⭐⭐⭐
Energy-0.2%+0.4%-2.4%19.6
49/100⭐⭐⭐
Consumer Cyclical+0.3%-3.1%-2.8%43.3
14/100
Technology-1.6%-0.3%-3.1%42.2
14/100
Industrials-0.5%-1.3%-8.9%30.4
10/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-26.